MediPharm Labs (MEDIF) announced the signing of a definitive supply agreement with Remidose Aerosols for the shipment of GMP-certified medicinal cannabis products to Costa Rica. Under the agreement, MediPharm Labs will supply a range of GMP-certified cannabis products including oils, tinctures, metered dose inhalers and dried flower to Remidose’s affiliated entity, Remidose LATAM. Remidose LATAM has already advanced its regulatory process, and shipment will begin once the remaining requirements are completed.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MEDIF:
- MediPharm Labs Poised to Gain as U.S. Moves Cannabis to Schedule III
- Medipharm Labs ‘welcomes’ executive order on cannabis reclassification
- MediPharm Labs Announces Board Changes: Michael Bumby Returns
- MediPharm Labs Enters French Medicinal Cannabis Market with First Shipment
- Medipharm Labs completes first shipment to France